Table 3.
CircRNAs as diagnostic and prognostic biomarkers for GC
| CircRNA | CircBase ID | Sample | Dysregulation in GC | Clinicopathological association | Potential function | AUC | Sensitivity and specificity | Refs. |
|---|---|---|---|---|---|---|---|---|
| Hsa_circ_0003159 | Hsa_circ_0003159 | Paired GC and GCN tissues (n = 108) | ↓ | Gender, stage, distal metastasis, tumor node metastasis | Diagnosis | 0.75 | 85.2%, 56.5% | [121] |
| CircFAT1(e2) | Hsa_circ_0001461 | Paired GC and GCN tissues (n = 38) GC cell lines | ↓ | Metastasis, TNM stage | – | – | – | [102] |
| Circ-104916 | Hsa_circ_0008383 | Paired GC and GCN tissues (n = 70) GC cell lines | ↓ | Invasion depth, tumor stage, lymphatic metastasis | – | – | – | [93] |
| Hsa_circ_0000096 | Hsa_circ_0000096 | Paired GC and GCN tissues (n = 101) GC cell lines | ↓ | Gender, invasion, TNM stage | Diagnosis | 0.82 | – | [105] |
| CircRNA_100269 | Hsa_circ_0013048 | Paired GC and GCN tissues (n = 112) GC cell lines | ↓ | Histological subtype, node invasion number | Prognosis | – | – | [91] |
| CircLARP4 | Hsa_circ_0003222 | GC and GCN tissues (n = 80) GC cell lines | ↓ | Tumor size, lymphatic metastasis | Prognosis | – | – | [117] |
| CircYAP1 | Hsa_circ_0002320 | Paired GC and GCN tissues (n = 97) | ↓ | Tumor size, TNM stage | Prognosis | – | – | [96] |
| CircPVRL3 | Hsa_circ_0066779 | Paired GC and GCN tissues (n = 62) GC cell lines | ↓ | TNM stage | Diagnosis | 0.763 | 90.3%, 56.4% | [107] |
| Hsa_circ_0074362 | Hsa_circ_007436 | GC and GCN tissues (n = 127) Gastritis tissues (n = 83) GC cell lines | ↓ | CA19–9, lymphatic metastasis | Diagnosis | 0.63 | 36.2%, 84.3% | [122] |
| Hsa_circ_0001895 | Hsa_circ_0001895 | GC and GCN (n = 96) Gastric mucosa tissues (n = 35) Gastric dysplasia tissues (n = 30) GC cell lines | ↓ | Cell differentiation, Borrmann type, CEA | Diagnosis | 0.792 | 67.8%, 85.7% | [123] |
| Hsa_circ_0014717 | Hsa_circ_0014717 | Paired GC and GCN tissues (n = 96) Gastric juice (n = 38) Gastric ulcer (n = 30) Chronic atrophic gastritis (n = 15) GC tissues (n = 39) | ↓ | Tumor stage, distal metastasis, tissue CEA and CA19-9 | Diagnosis | 0.696 | 59.4%, 81.3% | [74] |
| Hsa_circ_0000705 | Hsa_circ_0000705 | Paired GC and GCN tissues (n = 96) Gastric mucosa tissues (n = 35) Gastric ulcer tissues (n = 16) Erosive gastritis tissues (n = 18) Gastric dysplasia tissues (n = 25) | ↓ | Tumor location, stage, Borrmann type, pathologic diagnosis, CA19-9 | Diagnosis | 0.719 | 64.6%, 69.8% | [124] |
| CircPDSS1 | Hsa_circ_0093398 | Paired GC and GCN tissues (n = 20) GC cell lines | ↑ | – | Prognosis | – | – | [87] |
| Hsa_circ_0058246 | Hsa_circ_0058246 | Paired GC and GCN tissues (n = 43) | ↑ | Lymph node invasion(>=16), recurrence | Prognosis | – | – | [73] |
| Hsa_circ_0047905, Hsa_circ_0138960, Has-circRNA7690-15 | Hsa_circ_0047905, Hsa_circ_0138960, - | GC and GCN tissues (n = 31) GC cell lines | ↑ | – | Diagnosis | 0.85, 0.647, 0.681 | – | [108] |
| CircPVT1 | Hsa_circ_0001821 | Paired GC and GCN tissues (n = 187) | ↑ | T4 stage tumors, neural invasion | Prognosis | – | – | [75] |
| CiRS-7 | Hsa_circ_0001946 | Paired GC and GCN tissues (n = 102) | ↑ | TNM stage, lymph node involvement, distant metastasis | Prognosis | – | – | [80] |
| CircHIPK3 | Hsa_circ_0000284 | Paired GC and GCN tissues (n = 63) | ↑ | T stage, Ming’s classification | – | – | – | [84] |
| CircRNA_001569 | Hsa_circ_001569 | Paired GC and GCN tissues (n = 30) GC cell lines | ↑ | Tumor size, clinical stage, invasion | – | – | – | [85] |
| Circ-SFMBT2 | Hsa_circ_0017639 | Paired GC and GCN tissues (n = 36) Plasma samples from 26 GC patients and 18 healthy controls GC cell lines | ↑(GC tissues) ↑(GC plasma) | Tissues: TNM stage | Diagnosis | 0.759 (Tissues) | 80.6%, 63.9% | [89] |
| Hsa_circ_0006633 | Hsa_circ_0006633 | Paired GC and GCN tissues (n = 96) Healthy gastric mucosa (n = 35) Gastritis mucosa (n = 51) Gastric dysplasia tissues (n = 20) Paired plasma samples from GC patients and healthy controls (n = 20) GC cell lines | ↓(GC, gastritis and dysplasia tissues and GC cells) ↑(GC plasma) | Tissues: Distal metastasis, CEA | Diagnosis | 0.741 (Tissues) | 60%, 81% | [125] |
| Hsa_circ_002059 | Hsa_circ_002059 | Paired GC and GCN tissues (n = 101) Paired pre- and post-operative plasma sample (n = 36) | ↓(GC tissues) ↑(preoperative plasma) | Tissues: TNM stage, distal metastasis, gender, age | Diagnosis | 0.73 | 81%, 62% | [126] |
| Hsa_circ_0001649 | Hsa_circ_0001649 | Paired GC and GCN tissues (n = 76) Paired preoperative and postoperative blood samples (n = 20) | ↓(GC tissues) ↓(preoperative plasma) | Tissues: Pathological differentiation | Diagnosis | 0.834 (Tissues) | 71.1%, 81.6% | [127] |
| Circ_0027599 | Hsa_circ_0027599 | Paired GC and GCN tissues (n = 78) Blood samples from GC patients and healthy controls | ↓(GC tissues) ↓(GC blood) | Tissues: Tumor size, invasion, lymph node distant metastasis, distant metastasis, TNM stage | – | – | – | [104] |
| Circ-KIAA1244 | Hsa_circ_0130810 | Paired GC and GCN tissues (n = 28) Plasma samples from 62 GC patients and matched 25 healthy controls GC cell lines | ↓(GC tissues and cell lines) ↓(GC serum) | Plasma: TNM stage, lymphatic metastasis | Diagnosis Prognosis | 0.748 (Plasma) | 77.4%, 68.0% | [128] |
| Hsa_circ_0000190 | Hsa_circ_0000190 | Paired GC and GCN tissues (n = 104) Paired plasma samples from GC patients and healthy controls (n = 104) | ↓(GC tissues) ↓(GC plasma) | Tissues: Tumor diameter, lymphatic metastasis, distal metastasis, TNM stage, CA19-9 Plasma: CEA | Diagnosis | 0.75 (Tissues) 0.60 (Plasma) | 72.1%, 68.3% (Tissues) 41.4%, 87.5% (Plasma) | [113] |
| Hsa_circ_0000745 | Hsa_circ_0000745 | GC and GCN tissues (n = 80) Paired plasma samples from GC patients and healthy controls (n = 60) | ↓(GC tissues) ↓(GC plasma) | Tissues: Tumor differentiation Plasma: Tumor node metastasis, stage | Diagnosis | 0.683 (Plasma) | 85.5%, 45% | [114] |
| Hsa_circ_0000181 | Hsa_circ_0000181 | Paired GC and GCN tissues (n = 115) Paired plasma samples from GC patients and healthy controls (n = 102) | ↓(GC tissues) ↓(GC plasma) | Tissues: Tumor diameter, lymphatic metastasis, distal metastasis, CA19-9 Plasma: Differentiation, CA19-9 | Dignosis | 0.756 (Tissues) 0.582 (Plasma) | 53.9%, 85.2% (Tissues) 99.0%, 20.6% (Plasma) | [129] |
| Hsa_circ_0001017, Hsa_circ_0061276 | Hsa_circ_0001017, Hsa_circ_0061276 | Paired GC and GCN tissues (n = 121) Paired plasma samples from GC patients and healthy controls (n = 121) | ↓(GC tissues) ↓(GC plasma) | Tissues: Age, tumor size, TNM stage, distal metastasis, CEA Plasma: Gender, tumor size, differentiation, poor prognosis | Prognosis Diagnosis | 0.966 (Combinative AUC) | 95.5%, 95.7% | [78] |
| Hsa_circ_0000520 | Hsa_circ_0000520 | Paired GC and GCN tissues (n = 56) Plasma samples from 45 GC patients and matched 17 healthy controls | ↓(GC tissues) ↓(GC plasma) | Tissues: TNM stage Plasma: CEA | Diagnosis | 0.613 (Tissues) 0.897 (Plasma) | 53.6%, 85.7% (Tissues) 82.4%, 84.4% (Plasma) | [112] |